Abstract
We would like to report additional data concerning the results of allogeneic stem-cell transplantation for myelofibrosis with myeloid metaplasia, which were recently summarized by Tefferi (April 27 issue).1 Since our initial report,2 we have collected data on 11 new patients and have obtained further follow-up information on the original 55 patients. In an analysis of the overall group of 66 patients, the neutrophil-recovery rate remains high, rising to 84 percent by day 30. In a multivariate analysis, factors that remain associated with delayed engraftment are a low dose of nucleated cells, the absence of a pretransplantation splenectomy, and osteomyelosclerosis. We now find, in addition, that a pretransplantation hemoglobin level of less than 10 g per deciliter is associated with delayed neutrophil engraftment (P=0.043), a finding that may explain why patients with severe anemia have a worse outcome. With regard to acute graft-versus-host disease, we confirm that osteomyelosclerosis is a risk factor for grade III or IV acute graft-versus-host disease (incidence, 40 percent vs. 13 percent; P=0.027). In addition, this analysis shows that total-body irradiation is associated with grade II to IV acute graft-versus-host disease. Finally, a new multivariate analysis shows the influence of the recipient's age on five-year overall survival (14 percent for patients ≥45 years old vs. 62 percent for those 3,4 who are less than 40 years old, for whom planning a transplantation after the age of 45 years may not be the optimal strategy.